Merck, Vertex could beat expectations despite more subdued 1Q biopharma earnings anticipated: BofA...

Published on 12 Apr 2024 on Investing.com

Merck, Vertex could beat expectations despite more subdued 1Q biopharma earnings anticipated: BofA

Read the rest of the article

Start tracking your investments with Statfolio

Corporate earnings came to the market’s rescue in the past week, helping to overcome rate fears. ...

Benzinga 11 hours ago

Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? A recent academic case study, pub...

Benzinga via Yahoo Finance 24 Apr 2024

Key Insights Significantly high institutional ownership implies BeiGene's stock price is sensitiv...

Simply Wall St. via Yahoo Finance 23 Apr 2024

In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our ...

Insider Monkey via Yahoo Finance 22 Apr 2024

During these busy times, it pays to stay on top of the latest profit opportunities. And today’s b...

InvestorPlace via Yahoo Finance 22 Apr 2024

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.56%

Investing.com 19 Apr 2024

Tuesday, Amgen Inc AMGN provided an update regarding the results of the Phase 2a COURSE trial for...

Benzinga 17 Apr 2024

The VanEck Biotech ETF (BBH) was launched on 12/20/2011, and is a passively managed exchange trad...

Zacks via Yahoo Finance 15 Apr 2024

Despite the entry of discounted biosimilars, AbbVie (ABBV) has maintained 96% market share for it...

Seeking Alpha 13 Apr 2024

Merck, Vertex could beat expectations despite more subdued 1Q biopharma earnings anticipated: BofA

Investing.com 12 Apr 2024